Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Srilatha Edupuganti, Bethany Coomes, Kathryn E. Stephenson et al.|The Lancet HIV|2024

Cited by 12